MedImmune has announced that it is increasing its planned delivery of FluMist (Influenza Virus Vaccine Live, Intranasal) up to a total of three million doses. Originally the company had completed pr
Atrix Laboratories, Inc. has announced today that the company has signed a limited feasibility agreement with Aventis SA (NYSE: AVE) to begin preliminary research on two proprietary Aventis compounds
Boehringer Ingelheim has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tipranavir. The Company is seeking accelerated
Rosiglitazone, a drug taken to help improve blood sugar levels, also helps boost the effectiveness of a treatment for opening clogged arteries, according to a study in the November issue of Diabetes Care.People who have diabetes are far more li
In the midst of the current national shortage of influenza vaccine, the Infectious Diseases Society of America (IDSA) has renewed its call for Congress and the Administration to implement innovative
Following the worldwide withdrawal of Vioxx (rofecoxib), the European Medicines Agency (EMEA) has been asked by the European Commission, as a precautionary measure, to conduct a review of COX-2 inhibi
In an effort to continue to protect Michigan's seniors and vulnerable citizens without drug insurance coverage, Attorney General Mike Cox is pushing for disclosure of the prices of the most commonly-
A new drug to combat obesity at a cellular level is in the sights of a University of Queensland scientist. Dr Jon Whitehead, from the Centre for Diabetes and Endocrine Research, has identified a
Alzheimer's disease is characterized by progressive loss of cognitive function due to amyloid-beta (A? deposits in the central nervous system. If these deposits could be stopped or slowed, Alzheimer's disease might become more manageable.In the
The first new TB vaccine for more than 80 years has successfully come through safety trials in the UK. The vaccine, devised by a team led by Dr Helen McShane in Oxford's Centre for Clinical Vaccinology
Date: Wednesday, 7-Feb-2007
The World Health Organization on Thursday cautioned the Thai government on its decision to allow the country to produce a lower-cost version of Abbott Laboratories' antiretroviral drug Kaletra by granting a compulsory license for the drug, the Bangkok Post reports (Treerutkuarkul, Bangkok Post, 2/2).Thailand's Ministry of Public Health last week said that it had broken a patent on Kaletra by issuing a compulsory license and Health Minister Mongkol na Songkhla announced that the compulsory license was signed into law and took effect on Jan. 26.
World Trade Organization regulations allow governments to declare a "national emergency" and issue compulsory licenses without consulting the foreign patent owner.
Thailand, which has 580,000 people living with HIV/AIDS, has won international recognition for its quick launch of a national drug program that treats more than 82,000 HIV-positive people.
However, the government's commitment to providing universal access to care is facing increasingly high drug costs.
The compulsory license could save the country as much as $24 million annually (Kaiser Daily HIV/AIDS Report, 1/30).
WHO Director-General Margaret Chan during a visit to Thailand's National Health Security Office said the country should negotiate the price of Kaletra with Abbott before issuing a compulsory license and encouraged the nation's public health ministry to improve its relationship with drug companies.
"I'd like to underline that we have to find a right balance for compulsory licensing," Chan said, adding, "We can't be naive about this. There is no perfect solution for accessing drugs in both quality and quantity."
Nimit Tienudom, president of Thailand's AIDS Access Foundation, said that Chan's position was "disappointing" and that WHO "should have supported drug access and promoted the study of quality and inexpensive drugs for the sake of the global population rather than supporting pharmaceutical giants."
Mongkol did not comment on Chan's position, according to the Post.
Approximately 108,000 of people living with HIV/AIDS in Thailand depend on GPO-VIR, a generic, first-line antiretroviral produced by the country's Government Pharmaceutical Organization.
About 20,000 HIV-positive people have developed resistance to the drug and require Kaletra.
The country's Pharmaceutical Research and Manufacturers Association has said that it disapproves of the license and that it could lead to Thailand's isolation from the global biotechnology community, the Post reports (Bangkok Post, 2/2).
This article is republished with kind permission from our friends at the The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is published for Kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. Copyright 2007 Advisory Board Company and Kaiser Family Foundation. All rights reserved.